Powered by the firm’s LoopRNA in situ hybridisation (ISH) technology, the AMPIVIEW platform features products for human papillomavirus (HPV) detection and analysis.
The new platform will help the company expand its presence in the oncology market as well as open the way for it to move into the spatial biology market.
The AMPIVIEW RNA platform brings together the precision of targeted and sequence-particular probes with the sensitivity of the new LoopRNA ISH technology.
The platform’s design facilitates sensitive and specific detection of target genes in tissue or cell samples while ensuring that morphology is preserved.
HPV testing, which is part of Enzo’s focus on women’s health and oncology, is said to complement the existing offering of the firm’s POLYVIEW immunohistochemistry (IHC) and PATHO-GENE ISH detection platforms.
Enzo Biochem stated that the application of the AMPIVIEW visualisation technology to HPV analysis is a ‘logical’ expansion of the company’s existing wide portfolio of tissue analysis assays and reagents.
Enzo Biochem CEO Hamid Erfanian said: “Our outstanding team of scientists at Enzo developed the new LoopRNA ISH technology with clinical pathology in mind.
“The AMPIVIEW RNA platform is flexible and adaptable, with established manual or automated workflows. This product will support the advancement of drug discovery and development and help close the spatial biology gap in clinical pathology.”
Enzo Biochem is a provider of molecular diagnostics that mainly focuses on the development of advanced diagnostic platform technologies.